Clinical Trials in Busan, Busan Metropolitan City
2 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-Negative Breast Carcinoma+2 more
Olema Pharmaceuticals, Inc.1,000 enrolled85 locationsNCT07085767
Recruiting
Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
Mycosis FungoidesSezary Syndrome
Kyowa Kirin Co., Ltd.15 enrolled6 locationsNCT07132567